drugset / Trial / NCT01009970
Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter study phase II, open-label for cardiopathic patients affected by Non-Hodgkin's lymphoma diffuse large B cell CD20 + grade IIIb follicular. The purpose is to study the feasibility of R-COMP in this cohort of patients.
Timeline
- Start
- 2010-05
- Primary completion
- 2011-05
- Completion
- 2012-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 750 mg/m2 | — |
| Subject | Doxorubicin | Other / unclassified | 50 mg/m2 | — |
| Subject | Prednisone | Other / unclassified | 40 mg/m2 | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Subject | Vincristine | Small molecule | 1.4 mg/m2 | — |